238 related articles for article (PubMed ID: 26666270)
1. Practical considerations in the management of proton-pump inhibitors.
Aguilera-Castro L; Martín-de-Argila-dePrados C; Albillos-Martínez A
Rev Esp Enferm Dig; 2016 Mar; 108(3):145-53. PubMed ID: 26666270
[TBL] [Abstract][Full Text] [Related]
2. The use of proton pump inhibitors in children: a comprehensive review.
Gibbons TE; Gold BD
Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors--their pharmacological impact on the clinical management of acid-related disorders.
Klotz U
Arzneimittelforschung; 2009; 59(6):271-82. PubMed ID: 19634508
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.
Tjon JA; Pe M; Soscia J; Mahant S
Pharmacotherapy; 2013 Sep; 33(9):956-71. PubMed ID: 23712734
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.
Richardson P; Hawkey CJ; Stack WA
Drugs; 1998 Sep; 56(3):307-35. PubMed ID: 9777309
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
9. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Clark DW; Strandell J
Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
[TBL] [Abstract][Full Text] [Related]
10. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in chirally pure proton pump inhibitors.
Pai V; Pai N
J Indian Med Assoc; 2007 Aug; 105(8):469-70, 472, 474. PubMed ID: 18236913
[TBL] [Abstract][Full Text] [Related]
12. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.
Graham DY; Tansel A
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):800-808.e7. PubMed ID: 28964908
[TBL] [Abstract][Full Text] [Related]
13. Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Yaghoobi M; Padol S; Yuan Y; Hunt RH
Eur J Gastroenterol Hepatol; 2010 May; 22(5):583-90. PubMed ID: 20061959
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Remák E; Brown RE; Yuen C; Robinson A
Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
[TBL] [Abstract][Full Text] [Related]
15. [Protonic pump inhibitors in kidney transplant patients: efficacy and safety].
Cianciolo G; Feliciangeli G; Comai G; Stefoni S
Minerva Urol Nefrol; 2007 Jun; 59(2):207-15. PubMed ID: 17571057
[TBL] [Abstract][Full Text] [Related]
16. Management of reflux esophagitis: does the choice of proton pump inhibitor matter?
Labenz J; Armstrong D; Leodolter A; Baldycheva I
Int J Clin Pract; 2015 Jul; 69(7):796-801. PubMed ID: 25721889
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.
Ward RM; Kearns GL
Paediatr Drugs; 2013 Apr; 15(2):119-31. PubMed ID: 23512128
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of proton pump inhibitors anti-ulcer drugs use in the Araba district primary care area].
Martínez Gorostiaga J; Echevarría Orella E; Calvo Hernáez B
Rev Esp Salud Publica; 2018 Aug; 92():. PubMed ID: 30100604
[TBL] [Abstract][Full Text] [Related]
19. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Jonasson C; Tvete IF; Hatlebakk JG
Scand J Gastroenterol; 2013 Sep; 48(9):1010-7. PubMed ID: 23859491
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
Higginbotham TW
Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
